Search research articles
Contact Us
Filters
Showing results (291-300 of 509) with videos related to
Page
of 51
Sort By:
Bulletin Du Cancer
|
September 10, 2025
[Understanding biology to identify new therapeutic targets beyond chemotherapy in ovarian granulosa cell tumors]
Sil Endale Ahanda, Alexandra Lainé, Brunhilde Hanvic, et al.
Journal of Gynecologic Oncology
|
December 22, 2024
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)
Jung-Yun Lee, David Tan, Isabelle Ray-Coquard, et al.
Cancer Research
|
February 27, 2009
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome
Michael Gobert, Isabelle Treilleux, Nathalie Bendriss-Vermare, et al.
BMC Cancer
|
February 8, 2013
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
Jean-Yves Blay, Antoine Italiano, Isabelle Ray-Coquard, et al.
The Oncologist
|
January 31, 2012
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)
Isabelle Ray-Coquard, Antoine Italiano, Emmanuelle Bompas, et al.
International Journal of Clinical Oncology
|
August 13, 2013
Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhône-Alpes region
Pierre Etienne Heudel, Philippe Cousin, Antoine Lurkin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 7, 2016
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting
Stéphane Bouchet, Sylvie Poulette, Karine Titier, et al.
JCO Precision Oncology
|
July 2, 2025
Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer
Yann Christinat, Intidhar Labidi-Galy, Liza Ho, et al.
The Oncologist
|
May 11, 2025
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network
Nicolas Rippstein, Christophe Zemmour, Manuel Rodrigues, et al.
International Journal of Cancer
|
February 24, 2006
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis
Jacques-Olivier Bay, Isabelle Ray-Coquard, Jérôme Fayette, et al.
Page
of 51
Search research articles
Search
Showing results (291-300 of 509) with videos related to
Sort By:
Page
of 51
Bulletin Du Cancer
|
September 10, 2025
[Understanding biology to identify new therapeutic targets beyond chemotherapy in ovarian granulosa cell tumors]
Sil Endale Ahanda, Alexandra Lainé, Brunhilde Hanvic, et al.
Journal of Gynecologic Oncology
|
December 22, 2024
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)
Jung-Yun Lee, David Tan, Isabelle Ray-Coquard, et al.
Cancer Research
|
February 27, 2009
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome
Michael Gobert, Isabelle Treilleux, Nathalie Bendriss-Vermare, et al.
BMC Cancer
|
February 8, 2013
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
Jean-Yves Blay, Antoine Italiano, Isabelle Ray-Coquard, et al.
The Oncologist
|
January 31, 2012
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)
Isabelle Ray-Coquard, Antoine Italiano, Emmanuelle Bompas, et al.
International Journal of Clinical Oncology
|
August 13, 2013
Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhône-Alpes region
Pierre Etienne Heudel, Philippe Cousin, Antoine Lurkin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 7, 2016
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting
Stéphane Bouchet, Sylvie Poulette, Karine Titier, et al.
JCO Precision Oncology
|
July 2, 2025
Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer
Yann Christinat, Intidhar Labidi-Galy, Liza Ho, et al.
The Oncologist
|
May 11, 2025
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network
Nicolas Rippstein, Christophe Zemmour, Manuel Rodrigues, et al.
International Journal of Cancer
|
February 24, 2006
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis
Jacques-Olivier Bay, Isabelle Ray-Coquard, Jérôme Fayette, et al.
Page
of 51